drugset / Trial / NCT02750410

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

NCT02750410

Phase 4 Completed 159 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the efficacy and safety of combination therapy with dulaglutide and insulin in Japanese participants with type 2 diabetes.

Timeline

Start
2016-08
Primary completion
2018-06-18
Completion
2018-06-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Dulaglutide Peptide 0.75 mg Subcutaneous